I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies: an "inconvenient" truth?

Tools

Verburg, Frederik A., Giovanella, Luca, Iakovou, Ioannis, Konijnenberg, Mark W., Langsteger, Werner, Lassmann, Michael, Mihailovic, Jasna and Luster, Markus (2018) I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies: an "inconvenient" truth? European Journal of Nuclear Medicine and Molecular Imaging, 45 (13). pp. 2247-2249.

[thumbnail of I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies: an "inconvenient" truth?]

Preview

Text (I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies: an "inconvenient" truth?)
2018 EJNMMI Langsteger.pdf
Download (340kB) | Preview

Item Type:	Fachpublikation (peer reviewed)
Divisions:	Ordensklinikum Linz Barmherzige Schwestern > Nuklearmedizin
Depositing User:	Prof. Werner Langsteger
Date Deposited:	19 Mar 2019 11:42
Last Modified:	20 Apr 2022 09:52
URI:	https://eprints.vinzenzgruppe.at/id/eprint/8523

Actions (login required)

: View Item